

Barry Carter's Publications

(Refereed Research Papers)

1. **Carter BL**, Garnett WR, Pellock JM, Stratton MA, Howell JR. Effect of antacids on phenytoin bioavailability. *Therapeutic Drug Monitoring* 1981; 3:333-340.
2. **Carter BL**, Small RE, Garnett WR. Monitoring of patients receiving digoxin in two long term care facilities. *Journal of the American Geriatric Society* 1981; 29:163-168.
3. **Carter BL**, Reinders TP, Hamilton RA. Predicting maintenance warfarin dosage from initial patient response. *Drug Intelligence and Clinical Pharmacy* 1983; 17:23-26.
4. **Carter BL**, Helling DK, Burns EA, Johnson RE, Danielson SL. Association between appropriateness of prescribing and prescription documentation. *American Journal of Hospital Pharmacy* 1983; 40:1513-5.
5. Low RB, Jones ME, **Carter BL**, Cadoret RJ. The effect of D-amphetamine and ephedrine on smoking attitude and behavior. *Addictive Behaviors* 1984; 9:335-45.
6. **Carter BL**, Helling DK, Jones ME, Moessner H, Waterbury CA. Evaluation of family physician prescribing: Influence of the clinical pharmacist. *Drug Intelligence and Clinical Pharmacy* 1984; 18:817-21.
7. **Carter BL**, Helling DK, Jones ME, Friedman R, Ellsworth A. Multicenter study of Family Physician Prescribing. *Journal of Family Practice* 1984; 19:497-501.
8. True BL, **Carter BL**, Driscoll CE, House JD. Effect of a Rapid Diagnostic Method on Prescribing Patterns and Ordering of Throat Cultures for Streptococcal Pharyngitis. *Journal of Family Practice* 1986; 23:215-9.
9. **Carter BL**, Driscoll CE, Smith G. Theophylline clearance during pregnancy. *Obstetrics and Gynecology* 1986; 68:555-9.
10. **Carter BL**, Woodhead JC, Cole K, Milavetz G. Gastrointestinal side effects with erythromycin preparations. *Drug Intelligence and Clinical Pharmacy* 1987; 21:734-8.

11. **Carter BL**, Taylor JW, Becker A. Evaluation of three dosage-prediction methods for initial in-hospital stabilization of warfarin therapy. *Clinical Pharmacy* 1987; 6:37-45.
12. **Carter BL**, Barr W, Rock W, Taylor JW. Warfarin dosage predictions assisted by the analog computer. *Therapeutic Drug Monitoring* 1988; 10:69-73.
13. Boyle DA, Ludden TM, **Carter BL**, Becker A, Taylor JW. Evaluation of a Bayesian regression program for predicting warfarin response. *Therapeutic Drug Monitoring* 1989; 11:276-284.
14. **Carter BL**, Gersema LM, Williams GO, Schabold K. Long-acting, regular release and generic propranolol once daily for hypertension. *Pharmacotherapy* 1989; 9:17-22.
15. **Carter BL**, Kriesel HT, Steinkraus L, Knudson R. Antihypertensive prescribing by internists and family practitioners. *Journal of Family Practice* 1989; 29:257-262.
16. McMahon FG, Reder RF et al. The relationship of dose to the antihypertensive response of verapamil-sustained release in patients with mild to moderate essential hypertension. *J Clin Pharmacol* 1989; 29:1003-7.
17. BL, Butler CD, Bakht F, Miller JW. Decision-analysis as a quality assurance screening tool. *Family Medicine*. 992; 24:362-7.
18. Noyes MA, **Carter BL**, Helling DK et al. Evaluation of glyburide and glipizide in a health maintenance organization. *The Annals of Pharmacotherapy* 1992; 26:1215-20.
19. **Carter BL**, Noyes MA, Demmler RW. Differences in serum levels and responses to generic verapamil in the elderly. *Pharmacotherapy* 1993; 13:359-68.
20. **Carter BL**, Butler CD, Rogers JC, Holloway RL. Evaluation of Physician Decision-making with the use of prior probabilities and a Decision-analysis Model. *Archives of Family Medicine* 1993; 2:529-34.
21. Eselin JE, **Carter BL**, Johnston TP, Palmer WK. Effects of pravastatin on plasma lipid concentrations in poloxamer 407-induced hyperlipidemic rats. *Pharmacotherapy* 1995; 15:92-8.
22. Brown TER, **Carter BL**, Butler CD. Use of a decision analysis model to assist with therapeutic decisions made by pharmacists and pharmacy students. *Journal of Pharmaceutical Education* 1995; 59:14-20.

23. **Carter BL**, Noyes MA, Demmler RW, Barnette DJ, Pieper J. Pharmacokinetics of verapamil and its metabolites in elderly and young volunteers. *Journal of Applied Therapeutics* 1996; 1:85-91.
24. Porter JE, Brown TER, **Carter BL**, Noyes MA, Demmler RW. Age and gender-related differences in oral verapamil pharmacokinetics and pharmacodynamics. *Journal of Applied Therapeutics* 1996; 27-37.
25. Saseen, JJ, Jr., **Carter BL**, Brown TER, Elliott WJ, Black HR. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. *Hypertension* 1996; 28:109-114.
26. Park JJ, Kelley PA, **Carter BL**, Burgess P. Comprehensive pharmaceutical care in the chain setting. *Journal of the American Pharmaceutical Association* 1996; 36:443-51.
27. Saseen JJ, Porter JA, Barnette DJ, Bauman JL, Zajac EJ, **Carter BL**. Postabsorption concentration peaks with brand-name and generic verapamil: A double-blind, crossover study in elderly hypertensive patients. *J Clin Pharmacol* 1997; 37:526-34.
28. **Carter BL**, Barnette DJ, Chrischilles E, Mazzotti GJ, Asali ZJ. Evaluation of hypertensive patients aftercare provided by community pharmacists in a rural setting. *Pharmacotherapy* 1997; 17:1274-85.
29. Gandhi AJ, Murphy CM, Zervopoulos PC, Evans RE, **Carter BL**, Bauman JL. Evaluation of two forms of sustained-release nifedipine using 24 ambulatory blood pressure monitoring. *Amer J Hypertension* 1997; 10:992-6.
30. Alsuwaidan S, Billups S, **Carter B**, Malone D. Description of Ambulatory Care Services Provided by Veterans Affairs Medical Centers. *Amer J Health-Systems Pharmacists* 1998; 55:68-72.
31. **Carter BL**, Malone DC, Valuck RJ, Barnette DJ, Sintek CD, Billups, SJ. The IMPROVE* Study: Background and Study Designs (*Impact of Managed Pharmaceutical care on Resource and Outcomes in Veterans affairs medical centers). *Amer J Health-Systems Pharmacists* 1998; 55:62-67.
32. TR, Witt DM, Beall DG, **Carter BL**, Malone DC. Evaluation of excessive anticoagulation in a group model health maintenance organization. *Archives of Internal Medicine* 1998; :528-34.
33. Isaksen SF, Jonassen J, Malone DC, Billups SJ, **Carter BL** et al. Estimating risk factors for patients with potential drug-related problems using electronic pharmacy data. *Ann Pharmacother* 1999; 33:406-12.

34. Malone DC, Billups SJ, Valuck RJ, **Carter BL**. Development of a chronic disease indicator score using a Veterans Affairs medical center medication database. *J Clin Epidemiol* 1999; 52:551-7.
35. Billups SJ, Okano G, Malone D, **Carter BL** et al. Assessing the structure and process for providing pharmaceutical care in Veterans Affairs medical centers. *Am J Health-Syst Pharm* 2000; 57:29-39.
36. **Carter BL**, Malone D, Ellis S et al. Antihypertensive drug utilization in nine Veterans Affairs medical centers: The IMPROVE study. *Journal of Clinical Hypertension*. 2000; 2:172-80.
37. Ellis SL, Billups SJ, Malone DC, **Carter BL** et al. Ambulatory care clinical pharmacist interventions: The IMPROVE study. *Pharmacotherapy* 2000; 20:429-35.
38. **Carter BL**, Billups SJ, Malone DC et al. Recommended guidelines for pharmacists who provide care for patients in the IMPROVE study. *Federal Practitioner* 2001; (January):38-46.
39. Billups SJ, **Carter BL**, Malone DC. The relationship between medication non-compliance and patient characteristics, health-related quality of life, and health care costs. *Pharmacotherapy* 2000; 20:941-9.
40. Malone DC, **Carter BL**, Billups SJ et al. An economic analysis of a randomized, controlled, multicenter study of clinical pharmacist interventions for high-risk veterans: The IMPROVE study. *Pharmacotherapy* 2000; 20:1149-58.
41. Ellis SL, **Carter BL** et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: The IMPROVE study. *Pharmacotherapy* 2000; 20:1508-16.
42. Malone DC, **Carter BL**, Billups SJ et al. Can clinical pharmacists affect SF-36 scores in veterans at high-risk for medication-related problems? *Medical Care* 2001; 39:113-22.
43. **Carter BL** et al. How to IMPROVE ambulatory care: Guidelines for clinical pharmacists. *Federal Practitioner* 2001; (January):38-46.
44. Black HR, Elliott WJ et al. Baseline characteristics and early blood pressure control in the CONVINCe trial. *Hypertension* 2001; 37:12-18.
45. **Carter BL** et al. Interpreting the findings of the IMPROVE study. *The American Journal of Health-System Pharmacists* 2001; 58:1330-7.

46. Okano GJ, Malone DC, Billups SJ, **Carter BL** et al. Reduced quality of life in veterans at risk for drug-related problems. *Pharmacotherapy* 2001; 21:1123-9.
47. **Carter BL**, Lund BC, Hayase N, Chrischilles EA. The extent of antihypertensive drug interactions in a Medicaid population. *The American Journal of Hypertension* 2002; 15:953-7.
48. **Carter BL**, Chrischilles EA, Scholz D, Hayase N. The extent of services provided by pharmacists in the Iowa Pharmaceutical Case Management Study. *The Journal of the American Pharmaceutical Association* 2003; 43:24-33.
49. Zillich AJ, **Carter BL**, Ernst ME, Kelly MW. Effect of a telephone medication renewal service on blood pressure control. *J Am Pharm Assoc* 2003; 43:561-5.
50. Lund BC, Chrischilles EA, **Carter BL**, Ernst ME, Perry PJ. Development of a computer algorithm for defining an active drug list using an automated pharmacy database. *The Journal of Clinical Epidemiology* 2003; 56:802-6.
51. **Carter BL**, Lund BC, Hayase N, Chrischilles EA. A longitudinal analysis of antihypertensive drug interactions in a Medicaid population. *American Journal of Hypertension* 2004; 17:421-7.
52. Zillich AJ, McDonough RP, **Carter BL**, Doucette WR. Influential characteristics of physician/pharmacist collaborative relationships. *The Annals of Pharmacotherapy* 2004; 38:764-70.
53. Chrischilles EA, **Carter BL**, Lund BC, Rubenstein LM, Chen-Hardee SS, Voelker MD, Park TR, Kuehl AK. Evaluation of the Iowa Medicaid Pharmaceutical Case Management program. *J Am Pharm Assoc.* 2004; 44:337-49.

Published Research Abstracts (since 1991)

1. Noyes MA, **Carter BL**, Demmler RW, Pieper JA. Pharmacokinetic evaluation of generic and brand-name verapamil and its metabolites in elderly and young volunteers. *Pharmacotherapy* 1991; 11:100.
2. **Carter BL**, Noyes MA, Demmler RW. Pharmacokinetics and pharmacodynamics of verapamil and its metabolites in elderly subjects at steady-state. *Pharmacotherapy* 1991; 11:100.

3. **Carter BL**, Butler CD, Rogers JC et al. Evaluation of physician decision-making by using prior probabilities and a decision-analysis model. *Pharmacotherapy* 1992; 12:258.
4. **Carter BL**, Butler CD, Rogers JC et al. The use of decision-analysis techniques to change physician prescribing. *Pharmaceutish Weekblad Scientific edition* 1992; 14:E25.
5. Brown TER, **Carter BL**, Butler CD. Pharmacists' decision making with the use of prior probabilities and a decision analysis model. *Pharmacotherapy* 1993; 13:676.
6. Brown TER, **Carter BL**, Noyes MA, Demmler RW. Influence of age on pharmacodynamics of oral verapamil. *Pharmacotherapy* 1993; 3:676.
7. Eselin JA, **Carter BL**, Noyes MA, Demmler RW. Gender and age-specific verapamil pharmacokinetics. *Pharmacotherapy* 1993;13:676.
8. Ames N, Murphy C, Furmaga E, **Carter B**. Efficacy of twice daily verapamil in patients with hypertension. *Pharmacotherapy* 1993; 13:678.
9. **Carter BL**, Barnette DJ, Mazzotti GJ. The implementation of comprehensive pharmacy services in a rural primary care setting. *Pharmacotherapy* 1994; 14:351.
10. Park JJ, **Carter BL**, Burgess PP, Balow R. Implementation of comprehensive pharmaceutical services in a chain pharmacy setting. *Pharmacotherapy* 1994; 14:351.
11. Lewis RK, **Carter BL**, Glover DG. A description of clinical activities in an ambulatory pharmaceutical care center. *Pharmacotherapy* 1994; 14:350.
12. Barnette DJ, Kuehl PG, Paloucek F, **Carter BL**, Clark T. The evaluation of pharmaceutical care in the emergency department. FIP '94 Abstracts World Congress of Pharmacy 1994, 54th International Congress of FIP. Lisbon, Portugal, September, 1994.
13. Saseen JJ, **Carter BL**, Brown TER, Elliott WJ, Black HR. Comparison of nifedipine alone and in combination with diltiazem and verapamil in hypertension. *American Journal of Hypertension* 996; 9:150A.
14. Lousberg TR, Witt D, Beall DG, **Carter BL**. Evaluation of the management of outcomes of excessive anticoagulation in a group model health maintenance organization. *Pharmacotherapy* 1996; 16:508.

15. Saseen JJ, **Carter BL**, Brown TER, Elliott WJ, Black HR. Pharmacokinetics and pharmacodynamics of combined calcium channel blockers. *Pharmacotherapy* 1996; 16:126.
16. Billups SJ, **Carter BL**, Malone DC. Economic outcomes of medication noncompliance. *Pharmacotherapy* 1998;18:1174-5.
17. Billups SJ, Malone DC, Valuck RJ, **Carter BL**. Computerized development of a chronic disease indicator score using a prescription database. *Journal of the American Pharmaceutical Association* 1998; 38:263.
18. Malone DC, Billups SJ, Okano GJ, **Carter BL**. Assessing the structure and process for delivering pharmaceutical care in Veterans Affairs Medical Centers, The IMPROVE study. *Journal of the American Pharmaceutical Association* 1999; 39:268.
19. Malone DC, Okano GJ, Billups SJ, **Carter BL**. The relationship between quality of life and medication use in veterans: The IMPROVE study. *Journal of the American Pharmaceutical Association* 1999; 39:268.
20. Malone DC, **Carter BL**, Billups SJ. A randomized multicenter study evaluating the impact of clinical pharmacist services on resource utilization for patients at high risk for drug-related problems. *Pharmacotherapy* 1999; 19:504.
21. Saseen JJ, Borgelt LM, **Carter BL**, Rawlings JA. Efficacy of lovastatin 5 mg/day and 10 mg/day in reducing low-density lipoprotein cholesterol. *Pharmacotherapy* 1999; 19:485.
22. Ellis SL, Malone DC, **Carter BL**. Interventions performed by clinical pharmacists in high-risk ambulatory veterans: The IMPROVE study. *Pharmacotherapy* 1999; 19:1218.
23. Klem PM, Himstreet J, Bohnert K, **Carter B**, Levine J. Clinical and economic outcomes of treating *Helicobacter pylori* in patients taking chronic acid suppression therapy. *Pharmacotherapy* 1999; 19:1202.
24. **Carter BL**, Black HR, Elliott WJ et al. CONVINCe study: Baseline characteristics of enrolled patients. *International Pharmaceutical Abstracts* 1999; 2232.
25. Bazaldua OV, Plushner S, **Carter BL**, Ruscin MJ. Assessment of alendronate compliance in a managed care setting. *Pharmacotherapy* 2000; 20:344.
26. Ellis SL, **Carter BL**, Malone DC. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: The IMPROVE study. *Pharmacotherapy* 2000; 20:1281.

27. Ellis SL, **Carter BL** et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of diabetes in older adults: The IMPROVE study. *Pharmacotherapy* 2000; 20:1281.
28. Zillich A, **Carter BL**, Ernst M, Kelly M. Does a medication renewal service improve blood pressure control? *Pharmacotherapy* 2002; 22:427. Presented at the ACCP Spring Forum. Poster presentation.
29. Zillich A, **Carter BL**, Ernst M, Kelly M. Effect of medication renewal access on blood pressure control. American Society of Hypertension Annual meeting, American Journal of Hypertension 2002;15:37A. Poster presentation.
30. Tsuchiya I, Zillich A, **Carter BL**. Blood pressure control in a multi-disciplinary geriatric clinic. Presented at the Pharmacy Research Conference – Western Region, Denver, Colorado, June 1, 2002. Poster presentation.
31. Kaboli PJ, Hoth AB, **Carter BL**, Chrischilles EA, Shorr RI, Wagner P, Rosenthal GE. Lack of agreement between computerized medication profiles and structured medication histories. Presented at the 2002 Society of General Internal Medicine Annual Meeting.
32. Hoth AB, **Carter BL**, Schulte CK, Ness J, Shorr RI, Rosenthal GE, Kaboli PJ. Development of a new taxonomy to classify clinical pharmacy recommendations. Presented at the 2002 Annual meeting of the American College of Clinical Pharmacy, Albuquerque, New Mexico, October 2002. *Pharmacotherapy* 2002; 22:1342.
33. Zillich AJ, Doucette WR, **Carter BL**. A measurement tool for physician/pharmacist collaboration. Presented at the 2002 Annual meeting of the American College of Clinical Pharmacy, Albuquerque, New Mexico, October 2002. *Pharmacotherapy* 2002; 22:1342.
34. Physician/Pharmacist collaborative relationships. Presented at the 2nd American College of Clinical Pharmacy-European Society of Clinical Pharmacy International Congress, Paris, France, April 30, 2004.

Review Articles and Case Reports

1. **Carter BL**, Salter FJ. Review of Nalbuphine HCl. *Hospital Formulary* 1980; 15:849-856.

2. **Carter BL**, Small RE, Mandel MD, Starkman MT. Phenytoin induced hyperglycemia. *American Journal of Hospital Pharmacy* 1981; 38:1508-1512.
3. **Carter BL**. Labetalol. *Drug Intelligence and Clinical Pharmacy* 1983; 17:704-12.
4. True BL, **Carter BL**. Oral Acyclovir: An Update. *Clinical Pharmacy* 1984; 3:607-13.
5. True BL, Alexander B, **Carter BL**. Switching monoamine oxidase inhibitors. *Drug Intelligence and Clinical Pharmacy* 1985; 19:825-7.
6. **Carter BL**, Jones ME, Waickman LA. Management of Deep Vein Thrombosis and Pulmonary Embolism. *Clinical Pharmacy* 1985; 4:279-96.
7. Klamerus K, **Carter BL**. Congestive Heart Failure. Part I: Pathophysiology and approach to treatment. *Drug Topics* 1986; (July 7):1-8.
8. Klamerus K, **Carter BL**. Congestive Heart Failure. Part II: Specific agents. *Drug Topics* 1986; (August 4):1-6.
9. Eimer M, **Carter BL**. Elevated serum carbamazepine concentrations following diltiazem initiation. *Drug Intelligence and Clinical Pharmacy* 1987; 21:340-342.
10. **Carter BL**. Therapy Consultation: Anticoagulant therapy when pregnancy is complicated by steoporosis. *Clinical Pharmacy* 1987; 6:262-70.
11. **Carter BL**. Monthly columns have appeared in *Infectious Disease News* from August 1988 to the 1996.
12. Kannel WB, **Carter BL**. Initial drug therapy for hypertensive patients with hyperlipidemia. *The American Heart Journal* 1989; 118:1012-21.
13. Zenon GJ, Abob CV, **Carter BL** et al. Potential use of aldose reductase inhibitors to prevent diabetic complications. *Clin Pharm* 1990; 47:446-57.
14. **Carter BL**. Antihypertensive efficacy of beta blockers in the elderly. *Issues in Pharmacotherapy* January 1991.
15. **Carter BL**. Therapy of acute thromboembolism with heparin and warfarin. *Clin Pharm* 1991; 10:503-18.
16. **Carter BL**, Helling DK. Ambulatory Care: The Incomplete Agenda. *Ann Pharmacother* 1992; 26:701-8.

17. **Carter BL.** Collaboration between family physicians and clinical pharmacists. *Medifam (Spain)*. 1993; 3 (2):59-61.
18. Joint National Committee. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V). *Arch Intern Med* 1993; 153:154-83.
19. **Carter BL.** Fifth report of the Joint National High Blood Pressure Committee: A commentary. *Clinical Pharmacy* 1993; 12:53-7.
20. Furmaga EM, Murphy CM, **Carter BL.** Isolated Systolic Hypertension in Older Patients. *Clinical Pharmacy* 1993; 12:47-58.
21. Tortorice KL, **Carter BL.** Stroke prophylaxis: Hypertension management and antithrombotic therapy. *The Annals of Pharmacotherapy* 1993;27:471-9.
22. **Carter BL.** New goals set for fight against hypertension: Latest consensus report from the Joint National Committee outlines new strategies designed to improve drug therapy of high blood pressure. *U.S. Pharmacist* 1993; March:6-18.
23. **Carter BL.** Pharmaceutical Care for Hypertensive Patients. *American Pharmacy* 1994; NS34:54-63.
24. Brown TER, **Carter BL.** Hypertension and end-stage renal disease. *The Annals of Pharmacotherapy* 1994; 28:359-66.
25. Eselin J, **Carter BL.** Antihypertensive therapy and left ventricular hypertrophy. *Pharmacotherapy* 1994; 14:60-88.
26. **Carter BL,** Frohlich ED, Elliott WJ, Moore MA, Mann RJ, Roberts RW. Selected factors that influence antihypertensive response: choosing therapy for the patient. *Archives of Family Medicine* 1994; 3: 528-36.
27. **Carter BL.** Dosing of antihypertensive medications in patients with renal insufficiency. *Journal of Clinical Pharmacology* 1995; 35:81-6.
28. Lewis RK, **Carter BL,** Glover DG, Hutchinson RA. The Pharmaceutical Care Center: A Model for Ambulatory Care Pharmacy Practice. *American Journal of Health-Systems Pharmacists* 1995; 52:1793-7.
29. Barnette DJ, Murphy CM, **Carter BL.** Advanced ambulatory skill development programs for community pharmacists. *Journal of the American Pharmaceutical Association* 1996; 36:573-81.
30. Saseen JJ, **Carter BL.** Dual calcium channel blocker therapy for hypertension. *Annals of Pharmacotherapy* 1996; 30:802-10.

31. Jannsen RK, Murphy CM, Kendzierski DL, Harper Brown D, **Carter BL**, Furmaga EM et al. The ambulatory pharmaceutical care certificate program: Training pharmacists to meet the future. *American Journal of Health-Systems Pharmacists* 1996; 53:1018-23.
32. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. *Arch Int Med* 1997; 157:2413-46
33. **Carter BL**. Highlights of the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. *Am J Health-Syst Pharm* 1998; 55:382-7.
34. **Carter BL**. Optimizing delivery systems to tailor pharmacotherapy to cardiovascular circadian events. *Am J Health-Syst Pharm* 1998; 55(Suppl3): S17-S23.
35. **Carter BL**. Moderator (Introduction) to the symposium on "The expanding role of cardiovascular chronotherapeutics. *Am J Health-Syst Pharm* 1998; 55(Suppl 3): S3-S4.
36. Grier D, **Carter BL**, Malone D, Badger B. The University of Colorado School of Pharmacy and the University of Colorado Health Plan Forge a PBM Partnership. *J Managed Care Pharmacy* 1998; 4:478-80.
37. **Carter BL**. ISH in the Elderly: Is there a point beyond which pressure reduction is dangerous? *Medicographia* 1998; 32:659-71.
38. Billups SJ, **Carter BL**. Mibefradil: A new class of calcium-channel antagonists. *Annals of Pharmacotherapy* 1998; 20:43-4.
39. Booss J, **Carter BL** et al. National Stroke Association Stroke Prevention Guidelines. *Journal of Stroke and Cerebrovascular Diseases* 1998; 7:162-4.
40. **Carter BL**, Helling DK, Anderson J, Raebel M. Description of a formal affiliation between a school of pharmacy and a managed care organization. *Journal of Managed Care Pharmacy* 1999; 5:433-18.
41. **Carter BL** for the ASHP Commission on Therapeutics. ASHP Therapeutic Position Statement on Optimizing Treatment of Hypertension. *Amer J Health-Syst Pharm* 2000; 57:162-73.
42. **Carter BL**, Helling DK. Ambulatory care pharmacy services: Has the agenda changed? *Annals of Pharmacotherapy* 2000; 34:772-87.

43. **Carter BL**, Brunson BJ, Hatfield CL et al. Description of an introductory course designed to socialize pharmacy students. *Am J Pharm Ed* 2000; 64:166-173.
44. **Carter BL**, Cutler J, Pahor M, Weart CW (Consultants). Aggressive treatment of hypertension. *Patient Care* August 30, 2000; 14-48.
45. **Carter BL**. Clinical pharmacy in disease-specific clinics. *Pharmacotherapy*; 20:273s-277s.
46. **Carter BL**. The legacy of Iowa pharmacy. *The Journal of the Iowa Pharmacy Association* 2001 (July/August):10-11, 23-28.
47. **Carter BL**. Blood pressure as a surrogate end point for hypertension? *Annals of Pharmacotherapy* 2001; 36:87-92.
48. Zillich AJ, **Carter BL**. Eplerenone – A new selective aldosterone blocker. *The Annals of Pharmacotherapy* 2002; 36:1567-76.
49. **Carter BL**, Zillich AJ, Elliott WJ. How pharmacists can assist physicians with controlling blood pressure. *The Journal of Clinical Hypertension* 2003; 5:31-7.
50. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. *JAMA* 2003; 289:2560-72.
51. **Carter BL**. Hypertension: A review of therapeutic options. *P&T Digest* 2003; 12:34-44.
52. **Carter BL**, Zillich AJ. Pharmaceutical care services for patients with hypertension. *Ann Pharmacother* 2003; 37:1335-7.
53. Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Long Version. *Hypertension* 2003; 42:1206-52.

Editorials

1. **Carter BL**. Are you an academician? *Drug Intell Clin Pharm* 1989; 23:920-21.

2. **Carter BL.** A structure for pharmacy specialization. *Drug Intell Clin Pharm* 1990; 24:1113-4.
3. **Carter BL,** Barnette DJ. How many of us provide pharmaceutical care? *Pharmacother* 1996; 16:965-7.
4. **Carter BL,** Elliott WJ. The role of pharmacists in the detection, management, and control of hypertension: A national call to action. *Pharmacotherapy* 2000; 20:119-22.

National Committee Reports Published

1. **Carter BL,** Curry CE, Helling DK, Fedder DO, Forman H. Report of the Committee on Clinical Services in Community Pharmacy Practice. *American Journal of Pharmaceutical Education* 1986; 50:190-2.
2. **Carter BL.** (Chair) Practice guidelines for pharmacotherapy specialists. A position statement of the American College of Clinical Pharmacy. The ACCP Clinical Practice Affairs Committee, 1989-1990. *Pharmacother* 1990; 10:308-11.
3. **Carter BL.** (Chair) Practice guidelines for the clinical pharmacokinetics consultation service. The ACCP Clinical Practice Affairs Committee, 1989-1990. *Pharmacother* 1991; 1:175-7.
4. **Carter BL.** (Chair) Clinical pharmacy practice in the noninstitutional setting. The ACCP Clinical Practice Affairs Committee. 1990-1991. *Pharmacother* 1992; 12:358-64.
5. **Carter BL.** Chair Report of the Task Force on Faculty Models. (The AACP Section of Teachers of Pharmacy Practice. 1990-1991.) *American Journal of Pharmaceutical Education* 1992; 56:195-201.
6. **Carter BL.** (Chair). Guidelines for therapeutic interchange. A position statement of the American College of Clinical Pharmacy. The ACCP Clinical Practice Affairs Committee. 1990-1991. *Pharmacother* 1993; 13:252-56 and also published in *The Consultant Pharmacist* 1993; 13:252-6.
7. **Carter BL.** Chair Report of the Section of Teachers of Pharmacy Practice Task Force on Scholarship Definition and Evaluation. *American Journal of Pharmaceutical Education* 1994; 58:220-7.
8. Linn W, **Carter BL,** et al. Report of the ACCP Task Force on Ambulatory Care Clinical Pharmacy Practice: Guidelines for Establishing and Evaluating

Clinical Pharmacy Services in Primary Care. *Pharmacotherapy* 1994; 14:743-758.

9. **Carter BL.** Chair - Report of the Academic Sections Coordinating Committee. *American Journal of Pharmaceutical Education* 1997; 61:15-35 (Winter Supplement).
10. **Carter BL** (Secretary), Dent LA, Ernst ME at al. The Community Pharmacy Resource Kit. The 2001 Task Force on Community Pharmacy Practice, The American College of Clinical Pharmacy, Kansas City, MO, 2002.

Book Reviews

1. Noyes MA, **Carter BL.** Atherosclerosis Reviews: Volume 18: Hypercholesterolemia Clinical and Therapeutic Implications. *DICP, Ann Pharmacother* 1989; 23:263-4.

Monographs

1. **Carter BL,** Dobkin BH, Eastman E, Walleck CA. Stroke etiology and treatment. Syntex laboratories 1992.
2. **Carter BL,** Patterson H, Thomas OV, Weber M. New Product Bulletin: Losartan. American Pharmaceutical Association 1995.
3. Smolensky MH, **Carter BL.** New concepts in Pharmacy Practice: Chronopharmacology and Chronotherapeutics. Searle CE Program 1996.
4. **Carter BL,** Oparil S, Pieper JA, Roberts RW. A review of the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *APhA Special Report* 1998, pages 1-23.
5. Mustone Alexander L, **Carter BL,** Kemle KA, Pieper JA. A review of the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *AAPA/APhA Special Report* 1998, pages 1-20.
6. Pieper JA, **Carter BL,** Dobek MacKenzie D, Oparil S. Avapro (irbesartan). *AAPA/APhA New Product Bulletin* 1998; pages 1-13.

7. Pieper JA, **Carter BL**, Dobek MacKenzie D, Oparil S. Avapro (irbesartan). APhA New Product Bulletin 1998; pages 1-13.
8. Roberts ME, **Carter BL**, Pieper JA, Schebzamani F. Avapro (irbesartan). AANP/APhA New Product Bulletin 1998: pages 1-14.
9. Staff MB, Mustone Alexander L, **Carter BL**, Pieper JA. Avapro (irbesartan). AAPA/APhA New Product Bulletin 1998; pages 1-14.
10. Bainbridge JL, **Carter BL** (Editorial Advisors): Peer reports on the latest ACCP proceedings. Med/Pharm Forum 1998, pages 1-32.
11. **Carter BL**, Dent LA, Ernst ME et al. Community Pharmacy Resource Kit. American College of Clinical Pharmacy, Kansas City, 2002, 54 pages.

Book Chapters

1. Driscoll CE, **Carter BL**. Insomnia. In: Conn's Current Therapy. Rakel RE, ed. WB Saunders Company, Philadelphia, PA. 1986. pages 19-22.
2. **Carter BL**. Cancer Chemotherapeutic Agents. In: Primary Care Clinics. Driscoll CE, Ed. WB Saunders Company, Philadelphia, PA. 1987; 14:293-315.
3. **Carter BL**. Hypertension in the Elderly. In: Primary Care Clinics. 1989 Williams GO, Ed. WB Saunders Company, Philadelphia, PA. pages 395-410.
4. **Carter BL**. Pharmacotherapy and the Primary Care Physician. In: Primary Care Clinics. 1990.
5. **Carter BL**, Ed. WB Saunders Company, Philadelphia, PA. pages 469-77.
6. **Carter BL**, Bakht F. Therapy for Hypercholesterolemia. In: Primary Care Clinics. 1990,
7. **Carter BL**, Ed. WB Saunders Company, Philadelphia, PA. pages 479-97.
8. **Carter BL**. Ambulatory Care. In: The Handbook of Institutional Pharmacy Practice. 3rd Edition. 1992, Brown TR and Smith M. eds. American Society of Hospital Pharmacists, Bethesda, MD. pages 367-74.
9. **Carter BL**. Hematology: Coagulation. In: Basic Skills in Interpreting Clinical Laboratory Data. 1992, Traub SL, Ed. American Society of Hospital Pharmacists. Bethesda, MD. pages 183-95.

10. **Carter BL**, Helling DK. Patient Education and Chronic Disease Monitoring. In: Clinical Pharmacy and Therapeutics. 1992, Herfindal et al eds. Williams & Wilkins. Baltimore, Maryland. pages 82-92.
11. **Carter BL**, Furmaga EM, Murphy CM. Essential Hypertension. In: Applied Therapeutics: The Clinical Use of Drugs. Koda-Kimble MA et al eds. Applied Therapeutics, Inc. Vancouver, Washington. 1995, pages 10-1 to 10-33.
12. Gross JB, **Carter BL**. Hematology: Tests of Blood Coagulation. In: Basic Skills in Interpreting Clinical Laboratory Data. 2nd Edition, 1996, Traub SL, Ed. American Society of Health-System Pharmacists. Bethesda, MD. Pages 321-346.
13. **Carter BL**, Saseen JJ. Management of Hypertension. In: Carter BL et al Eds. The Pharmacotherapy Self-Assessment Program. 3rd Edition. The American College of Clinical Pharmacy, 1998, pages 1-36.
14. **Carter BL**. Management of Hypertension. In: Mueller et al Eds. The Pharmacotherapy Self-Assessment Program. 4rd Edition. The American College of Clinical Pharmacy, 2001; pages 1-44.
15. Saseen JJ, **Carter BL**. Essential Hypertension. In: Applied Therapeutics: The Clinical Use of Drugs. 7th Edition Koda-Kimble MA et al eds. Lippincott Williams & Wilkins, Philadelphia. 2001, pages 12-1 to 12-48.
16. Ruscin JM, **Carter BL**. Hypertension. In: Therapeutics in the Elderly, 3rd Edition. Harvey Whitney Books Company, Cincinnati, Ohio, 2001, pages 315-344.
17. **Carter BL**, Saseen JJ. Hypertension. In: Pharmacotherapy: A Pathophysiologic Approach, 5th Edition. DiPiro JT et al editors. McGraw-Hill, New York, 2002, pages 157-183.
18. Saseen JJ, **Carter BL**. Essential Hypertension. In: Applied Therapeutics: The Clinical Use of Drugs. 8th Edition Koda-Kimble MA et al eds. Lippincott Williams & Wilkins, Philadelphia,. (in press).
19. **Carter BL**, Zillich AJ. Management of Hypertension. In: Zarowitz, BJ et al Eds. The Pharmacotherapy Self-Assessment Program. 5th Edition. The American College of Clinical Pharmacy, 2004; pages 129-163.
20. Saseen JJ, **Carter BL**. Hypertension. In: Pharmacotherapy: A Pathophysiologic Approach, 5th Edition. DiPiro JT et al editors. McGraw-Hill, New York, (in press).

Books

1. Driscoll CE, Smith C, Bope E, **Carter BL**. Handbook of Family Practice. Yearbook Medical Publishers, 1st Edition Chicago, Ill. 1986, 685 pages.
2. Driscoll CE, Smith C, Bope E, **Carter BL**. The Family Practice Desk Reference. Mosby Year Book, 2nd Edition. St. Louis Missouri 1990, 703 pages.
3. **Carter BL** (Ed). Pharmacotherapeutics for the Primary Care Physician. 1990. WB Saunders Company, Philadelphia, PA. September, 1990, 241 pages.
4. **Carter BL**, Angaran D, Sisca T (Eds). The Pharmacotherapy Self-Assessment Program. The American College of Clinical Pharmacy, Kansas City, MO. 1991-1992.
5. **Carter BL**, Angaran D, Lake K, Raebel M (Eds). The Pharmacotherapy Self-Assessment Program. 2nd Edition. The American College of Clinical Pharmacy, Kansas City, MO. 1995-1996.
6. Driscoll CE, Bope E, **Carter BL**, Smith C. The Family Practice Desk Reference. Mosby Year Book, 3rd Edition. St. Louis Missouri 1996, 789 pages.
7. **Carter BL**, Lake K, Raebel M, et al (Eds). The Pharmacotherapy Self-Assessment Program. 3rd Edition. The American College of Clinical Pharmacy, Kansas City, MO. 1998-2000.